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Abstract
The tumors associated with bone are mostly of mesenchymal origin and contrib-
ute to approximately 1% of all the known tumors. These could be primary/benign 
tumors (that originate in the bone), secondary tumors (that originate in some other 
tissue/organ and metastasize to the bone), or malignant primary bone tumors 
(that originate in bone and metastasize to distant tissue). These tumors are majorly 
due to defects in the regulation of tumor suppressor genes and oncogenes and/or 
misregulation of signal transduction pathways. Chemotherapy and radiotherapy 
used for the treatment have several side effects. During the recent years, thera-
peutic strategies involving hormone deprivation (estrogen, androgen), hormone 
replacements (estrogen analogs), hormone receptor modulators (SERMs), growth 
factors and cytokines, small-molecule inhibitors, and gene therapy have emerged 
as a promising alternative to chemo- and radiotherapy. In the present chapter, we 
have provided an extensive account of tumors associated with the bone and vari-
ous therapeutic options related to hormone deprivation, hormone replacements, 
hormone receptor modulators, and hormone inhibition.
Keywords: osteosarcoma, chondrosarcoma, androgen, estrogen, metastasis, 
hormone
1. Introduction
Primary bone tumors are rare in occurrence accounting for approximately 0.2% 
of all the tumors. Generally, primary tumors are localized, intra-compartmental, 
or extended, extra-compartmental [1]. Most benign tumors that have not spread to 
lymph nodes or other organs remain asymptomatic until their presence is indicated 
by a trivial insult [1, 2]. Therefore, it becomes important to categorize bone lesions 
in the early stages of their development for prognosis and diagnosis [2]. On the 
other hand, skeletal metastases are frequent in patients with breast, prostate, and 
lung cancer and also occur in other tumors such as myeloma, thyroid and renal 
cancer, lymphoma, and Ewing’s sarcoma [3]. The bone becomes the most common 
site of metastases in humans due to its highly vascular nature, and this results in 
pain, pathologic fracture, and decreased quality of life [3].
Bone metastases are either osteolytic or osteoblastic, depending on the 
dominance of osteoclastic activity or osteoblasts, respectively [3]. As a result 
the radiological appearance of bone metastasis is lytic, sclerotic, or mixed [4]. 
General pathogenesis of bone tumors sequentially involves proliferation of primary 
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neoplasm, local tissue invasion, intravasation into blood vessels, extravasation into 
bone marrow, tumor cell dormancy, proliferation in bone, and modification of bone 
microenvironment [3]. The site of metastases is governed by the “seed and soil” 
hypothesis by Paget which states that neoplastic cells grow or proliferate only in a 
suitable environment [3]. Tumor cells therefore migrate to the heavily vascular-
ized areas of the skeleton, particularly the red bone marrow of the axial skeleton 
and the proximal ends of the long bones, the ribs, and the vertebral column [5]. 
Chemotactic factors such as CXCL10 (CXC motif ligand [CXCL]), CXCL12, and 
osteopontin have been reported to play a major role in tumor migration [6].
Tumors can be classified into low-grade (Grade I), intermediate-grade (Grade II),  
and high-grade (Grade III) tumors [1]. Grading of bone tumors is roughly based on 
the cellularity of the lesions compared to the extracellular matrix, nuclear features, 
the presence of mitotic figures, and necrosis [7]. Grade II tumors are more cellular, 
with a greater degree of nuclear atypia, hyperchromasia, and nuclear size. Grade 
III tumors have significant areas of marked pleomorphism, large cells with more 
hyperchromatic nuclei than Grade II tumors, occasional giant cells, and abundant 
necrosis [1]. High-grade bone tumors are the fastest growing and most aggressive 
group of classic osteoblastic subtype. On the basis of histological appearance, bone 
tumors are classified as parosteal and periosteal. Parosteal tumors belong to low-
grade subtype of osteosarcoma, whereas periosteal belongs to the intermediate-
grade subtype. Parosteal tumors have fibroblast appearance and are limited to bone 
surface, but periosteal tumors appear chondroblastic upon histology.
2. Primary malignant tumors
2.1 Giant cell tumor of bone (GCT)
This tumor accounts for 5% of all primary and 20% of the benign skeletal 
tumors [9]. GCT is an aggressive osteolytic benign bone tumor developing in the 
long bones, which is characterized by giant, multinucleated osteoclast-like cells, 
recruited by stromal cells such as osteoblasts [9, 10]. The stromal cells of GCT 
highly express parathyroid hormone-related peptide (PTHrP) and thus increase the 
bone tumor cell local invasiveness and migration [10].
Distal femur, proximal tibia, and distal radius are the most common locations for 
the occurrence of GCT, but due to its association with Paget’s disease, it may also occur 
in the skull, pelvis, facial bones, and spine. It has been reported to rarely affect greater 
trochanter of the femur. Though some of the reports claim an equal rate of occurrence 
in both the genders, some reports show an increased prevalence in females [9].
These tumors have been associated with reduction in length of telomeres [7]. 
Radiological examination in patients with closed physes displays lytic lesions with 
well-defined, non-sclerotic margins that are eccentric in location and extend near 
the articular surface. Thus GCT involves cortical expansion or destruction [9].
2.2 Chondrosarcoma
Chondrosarcomas majorly involve tumorous growth of chondrocytes, which 
are mostly found in bones that elongate due to endochondral ossification and 
involve differentiation in the epiphyseal growth plates of long bones. For example, 
hypertrophic chondrocytes are found in clear cell chondrosarcoma. The most 
common sites include proximal femur, proximal humerus, distal femur, and ribs. 
Sex hormones such as estrogen play a major role in governing the nuclear signaling 
pathways involved in this process of ossification [1].
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There are different histologic variants of chondrosarcoma.
1. Mesenchymal chondrosarcomas are highly aggressive tumors, composed of 
resting chondrocytes, and are radiographically and histologically similar to 
Ewing’s sarcoma [1, 11]. Such sarcomas frequently occur in the pelvic bones, 
femur, and humerus and less commonly in the head, spine, breast, and pros-
tate [1]. These have high risk of local recurrence and distant metastasis [11].
2. Dedifferentiated chondrosarcomas are aggressive neoplasms and have poor 
prognosis [11].
3. Clear cell chondrosarcomas are low-grade tumors and involve the epiphyseal 
end of the long bone. The radiographs show a lytic defect at the epiphyseal end 
of long bones, sharply demarcated with sclerotic margins [11].
4. Extraskeletal myxoid chondrosarcomas are slow-growing tumors, character-
ized histologically by prominent myxoid degeneration, and are considered as 
differentiated tumors [11].
5. Juxtacortical chondrosarcoma arises on the surface of the bone and is histo-
logically identical to conventional intramedullary chondrosarcoma [1].
2.3 Ewing’s sarcoma
Ewing’s sarcoma is an exception to all the bone tumors, because bone tumors are 
mostly mesenchymal in origin, but Ewing’s sarcoma is reported to have neuroecto-
dermal precursor cells [7]. It has been found to be associated with neuroblastomas 
in patients younger than 5 years, whereas in patients above 30 years, it is associated 
with small round cell tumors (e.g., small-cell carcinoma) and large-cell lymphoma 
[1]. Ewing’s sarcoma is most likely to occur in younger individuals and most com-
monly in males [12].
Ewing’s sarcoma is characterized by small round cell bone tumor and involves 
pain at the site of tumor and soft tissue swelling around it [1]. Unlike other primary 
tumors of the bone, Ewing’s sarcoma is associated with a characteristic transloca-
tion in the 11th and 22nd chromosomes. This translocation results in production of 
an aberrant transcription factor EWS/FLI1 that forms a complex with RNA helicase 
A and drives the pathogenesis of Ewing’s sarcoma [7, 12]. Its metastasis involves 
certain non-specific signs of inflammation, anorexia, fever, malaise, fatigue, and 
weight loss [1].
2.4 Osteosarcoma
Osteosarcoma is an osteoid-producing malignancy of mesenchymal origin [8]. It is 
the third most frequent type of cancer in adolescence and represents more than 56% 
of all bone tumors [13]. It is the most common bone sarcoma and affects 60% of the 
patients below 25 years of age and 30% of the patients above 40 years [14, 15]. It is 
associated with extensive genomic disruptions and propensity of metastatic spread. 
Seventy-six percent of the osteosarcomas have been found to be associated with 
reduced expression of HACE1 gene localized to human chromosome 6q21, thus result-
ing in poor survival [14]. Approximately, 30–40% children with pediatric osteosar-
coma die due to metastasis to lungs [1, 16].
Environmental factors such as exposure to radiation, teriparatide (parathyroid 
hormone 1–34) usage, and consumption of fluorinated drinking water during 
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childhood increase the risk of osteosarcoma [8]. Its localization in regions that 
are largely cut off from the vasculature reduces the effectiveness of systemically 
administered chemotherapeutics [17]. The subtypes of osteosarcoma include 
osteoblastic, chondroblastic, fibroblastic, small cell, telangiectatic, high-grade 
surface, extraskeletal, and other lower-grade forms of tumors including parosteal 
and periosteal [8].
Osteosarcomas are one of the widely studied sarcomas of the skeletal system. 
Several investigations have reported the association of germline mutation disorders 
such as hereditary retinoblastoma, Rothmund-Thomson syndrome, Li-Fraumeni 
syndrome, and Bloom syndrome, with increased risk of osteosarcoma [8]. Various 
other pathways discussed below have been reported to be responsible for support-
ing growth and metastasis of osteosarcoma.
1. Constitutively active signal transducers and activators of transcription 3 
(STAT3) signaling have been found to be necessary for osteosarcoma survival 
and migration in vitro and tumor growth in vivo. STAT3 is a proto-oncogene 
that stimulates self-proliferation (due to expression of cyclin D1), mediates 
immune evasion, promotes angiogenesis, and confers apoptosis resistance 
(induced by conventional therapies, due to expression of BCL2) [18]. Similarly 
an upregulation in the expression of survivin (an oncogenic protein) has also 
been observed in osteosarcoma (Figure 1) [19].
2. Attenuation of cell cycle arrest by p53 has been found to affect the upstream 
p53 signaling pathways [20]. Approximately 26.5% of non-hereditary osteo-
sarcomas have been reported to be associated with somatic loss of p53, out of 
which 60% are high-grade osteosarcomas, whereas 1% are low-grade osteo-
sarcomas [14]. Tumor suppressor genes such as p15 and p27 have been com-
monly found to be silenced due to methylation of promoter by DNA methyl 
transferase that adds methyl group to the fifth carbon position of cytosine ring 
in CpG islands, leading to heterochromatin and inhibition of gene expression 
(Figure 1) [21].
3. Sex steroid hormones have been found to play an important role in develop-
ment and progression of bone tumors. Previous investigations have revealed 
the role of aromatase and sulfatase pathways in the in situ formation of active 
estrogen. Aromatase pathway involves aromatization of androgens to produce 
estrogen. In sulfatase pathway, estrone 3-sulfate is taken up by the cells and 
is activated by the removal of sulfate by steroid sulfatase, thus converting 
inactive estrogen to unconjugated and bioactive estrogen. Both these path-
ways allow generation of estrogen and androgen by the bone cells in the bone 
microenvironment (Figure 2) [22].
4. Growth factors such as transforming growth factor (TGF)-β, insulin-like growth 
factors (IGFs), bone morphogenetic proteins (BMPs), platelet-derived growth 
factor (PDGF), and fibroblast growth factor (FGF) released from degraded 
bone matrices also promote tumor cell proliferation by production of PTHrP that 
interacts with parathyroid hormone (PTH)/PTHrP receptors in the bone and 
kidney to cause hypercalcemia, osteoclast-mediated bone resorption, increased 
nephrogenous cyclic AMP, and phosphate excretion [4–6, 23]. PTH is known 
to regulate osteosarcoma cells, by inducing transcription of c-Fos that in turn 
targets calcium/cAMP-response element (CRE) through activation of protein 
kinase A (PKA) [24]. c-Fos is a member of activator protein-1 (AP-1) family of 
transcription factors containing c-Fos (FosB, Fra-1, Fra-2) (Figure 1) [25].
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Additionally, FGF also regulates multiple signaling cascades in both autocrine 
and paracrine manner [4]. FGF receptor 1 was identified as a c-Fos-regulated gene 
playing an important role in lung metastases of osteosarcoma. The FGF receptors 
1–4 belong to a family of receptor tyrosine kinase (RTK) that triggers intracellular 
signaling cascades through mitogen-activated protein kinase (MAPK), phos-
phoinositide 3-kinase (PI3K)/protein kinase B (AKT), STAT pathways, and signal 
transducers phospholipase Cγ (PLCγ) and casitas B-lineage lymphoma (CBL) 
(Figure 1) [25].
5. Majority of the osteosarcomas develop as a result of metastases of breast, 
prostate, or lung tumors into the bone. Breast cancer cells metastasize to the 
bone and secrete various factors in the bone microenvironment that enhance 
osteoclastogenesis and inhibit osteoblastogenesis, thus developing several 
skeletal-related events (SREs) such as pathological fracture, spinal cord 
compression, bone pain, and hypercalcemia [26]. Similarly, androgen signal-
ing components such as androgen receptor, ARV7, v-ets avian erythroblastosis 
virus E26 oncogene homolog (ERG), cytochrome P450, and family 17 subfam-
ily A polypeptide 1 (CYP17) and molecules such as phospho-Met, phospho-
Src, glucocorticoid receptor, and Ki67 have been implicated to play a major role 
in the metastasis of castration-resistant prostate cancer (CRPC) [27].
Some of the reports associate migration and invasion of breast cancer cells to 
the upregulation of micro RNAs, miR-10b, miR-373, and miR-520c. Out of these, 
miR-373 and miR-520c have been found to silence CD44 gene that codes for hyal-
uronan receptor (plays an important in cellular adhesion). Similarly, miR-218 that 
is involved in osteoblast differentiation promotes breast cancer cell osteomimicry 
(ability to acquire bone cell phenotype for immune escape). miR-154 and miR-379 
overexpression in bone metastatic cells was associated with mesenchymal proper-
ties and enhanced invasive potential [28].
Figure 1. 
Cross talk of various signaling pathways in osteosarcoma. (i) JAK–STAT pathway confers apoptosis resistance, 
thus enhancing tumor cell survival. (ii) Inactivation of p53 favors cell cycle progression in cells with DNA 
damage and promotes tumorigenesis. (iii) Cross talk between GPCR-regulated PTHrP signaling and RTK-
mediated survival/growth factors. (iv) Role of RTK in supporting tumor cell survival and proliferation as a 
response to various growth factors. (v) Wnt signaling mechanism plays a major role in tumors associated with 
bone tissue.
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3. Pathophysiology of bone tumors
General pathogenesis of bone tumors sequentially involves proliferation of pri-
mary neoplasm, local tissue invasion, intravasation into blood vessels, extravasation 
into bone marrow, tumor cell dormancy, proliferation in the bone, and modification 
of bone microenvironment. The site of metastases is governed by the “seed and 
soil” hypothesis by Paget which states that neoplastic cells grow or proliferate only 
in a suitable environment [3].
The initial step in metastasis involves escape of cancer cells from primary 
tumor into the systemic circulation, through epithelial–mesenchymal transition 
(EMT). EMT involves loss of cell surface intercellular adhesion proteins and 
epithelial polarization. EMT is followed by dissolution of the extracellular matrix 
by secreting certain proteolytic enzymes and migration into surrounding tis-
sue to enter systemic circulation through intravasation. Such circulating tumor 
cells (CTCs) escape anoikis (cell apoptosis due to loss of cell-matrix or cell-cell 
interactions, preferably through overexpression of tyrosine kinase receptor, 
TrkB) resulting in activation of PI3K-AKT pro-survival pathways. These tumor 
cells also upregulate certain proteins on their surface (e.g., CD47) to escape 
destruction by macrophages [4]. The two major factors that govern the localiza-
tion of CTCs are blood flow and molecular signaling. For example, the metastasis 
of breast cancer to thoracic spine is due to the venous drainage of the breast to 
thoracic region, whereas lung cancer shows general skeletal distribution due 
to the drainage of pulmonary veins into the left side of the heart, followed by 
eventual entry into systemic circulation. Alternatively, prostate cancer majorly 
Figure 2. 
(A) Percentage of primary bone cancers in adult human population [61]. (B) Osteosarcoma cases per 100,000 
population per year [62]. (C) Percentage of males and females diagnosed with primary bone tumor in the 
United States in the year 2017 [61].
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displays metastasis to the axial skeletal in the lumbar spine, sacrum, and pelvis 
due to their drainage through pelvic plexus. As far as the signaling pathways are 
concerned, CXCL12-CXCR4 (CXC motif ligand [CXCL], CXC chemokine recep-
tor [CXCR]) axis has been found to regulate CTC homing to the bone. CXCL12, 
also called as stromal cell-derived factor 1 (SDF1), is a chemokine factor secreted 
by bone marrow MSCs, endothelial cells, and osteoblast and primarily binds to 
G protein-coupled receptor, CXCR4, thus activating cell survival, chemotaxis, 
and expression of integrin αvβ3 on the surface of CTCs [4]. Another receptor 
involved in osteotropism is the calcium-sensing receptor (CaSR), expressed by 
advanced primary breast tumors that causes enhanced calcium-induced migra-
tion to the bone [28]. In addition to CXCL12-CXCR4 axis, non-receptor cyto-
plasmic tyrosine kinase, Src, has also been shown to mediate improved survival 
of breast cancer cells in the bone marrow by increasing the resistance to tumor 
necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and activation 
of AKT signaling [4].
After tumor cells colonize the bone, they induce the expression of receptor 
activator of nuclear factor-κB ligand (RANKL) via production of PTHrP, prosta-
glandin E2 (PGE2), interleukin 6 (IL-6), IL-1β, TNF, and epidermal growth factor 
(EGF), which promote osteoclast differentiation and activation. RANKL induces 
osteoclastic bone resorption resulting in growth of osteolytic tumor that causes 
hypercalcemia, and it also acts as a chemoattractant to the bone for tumor cells [6]. 
In relation to this, hypoxia-inducible factor (HIF)-1α has been reported to act as an 
upstream master switch to many of the osteolytic factors such as IL-11 and IL-8 and 
angiogenic factors such as PDGF and vascular endothelial growth factor (VEGF) 
[4, 29]. TGF-β plays a central role in the pathogenesis of osteolytic bone metastasis 
from breast carcinoma via potentiation of estrogen receptor (ER)-α-mediated 
transcription induced by constitutively active ERα [23]. A higher expression of ERα 
in the cortical bone suggests its role in bone formation, whereas trabecular bone 
cells show a higher expression of ERβ [30].
Osteolytic bone metastases are most often caused by breast cancer and multiple 
myeloma [6, 31], whereas osteoblastic metastases are mostly observed in bone metas-
tasis of prostate cancer, which is due to osteoblast stimulation by cancer cells [6, 32]. 
Factors that are locally produced by cancer cells, such as bone BMP, IGF, FGF, TGF-β, 
and endothelin-1, also promote osteoblast proliferation and bone formation [6].
Another important cellular component of bone microenvironment that is 
involved in tumor metastases is osteocytes. Osteocytes present in the bone regulate 
osteoclast development through expression of RANKL, macrophage colony-
stimulating factor (M-CSF), and osteoprotegerin (OPG) and inhibit osteoblast 
differentiation by the expression of sclerostin. Osteocytes have an interesting 
ability to respond to mechanical stress and pressure. An increase in pressure due to 
prostate cancer metastasis thus results in upregulation of matrix metalloproteinases 
(MMPs) and chemokine (C-C motif) ligand 5 (CCL-5). Additionally, apoptotic 
osteocytes have been shown to release IL-11 that enhances osteoclast differentia-
tion. Endothelial cells are yet another important component of the bone marrow 
that contributes to the bone metastatic process. Endothelial cells in the metaphysis 
of the long bone aid CTC adhesion due to constitutive expression of P-selectin, 
E-selectin, vascular cell adhesion molecule 1 (VCAM1), and intercellular adhesion 
molecule A (ICAM-1). Decrease in shear forces due to reduced blood flow velocity 
in the large volume of sinusoids also favors CTC attachment [4].
The bone marrow is also a major reservoir for dendritic cells, macrophages, 
myeloid-derived cells, and different subsets of T cells. T and B cells are known 
to produce RANKL and impact osteoclastogenesis, whereas production of IL-6, 
IL-23, and IL-1 by dendritic cells in the bone microenvironment of multiple 
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myeloma patients causes an increase in Th17 cells that in turn increase IL-17. IL-17 
is an important cytokine that promotes osteoclast and myeloma proliferation 
and also mediates interactions between T cells and bone metastatic environment. 
Additionally, myeloid-derived suppressor cells from the bone marrow suppress 
innate and adaptive immune responses by impairing T-cell antigen recognition and 
promotion of regulatory T cells [4].
However, as an individual ages, the hematopoietic red bone marrow gets con-
verted to adipose tissue-rich yellow bone marrow that has a significant impact on 
the development of bone metastasis. These bone marrow adipocytes not only serve 
as an energy source but also secrete several pro-inflammatory mediators such as 
IL-1β, IL-6, leptin, adiponectin, VCAM-1, TNF-α, and CXCL12 that increase cancer 
cell survival and proliferation [4].
4. Tumor biomarkers
Histological examination of tissue biopsy has been the most commonly used 
procedure for the diagnosis of bone tumors. Clinical and radiological observations 
also aid in diagnosis and provide a complete staging of bone cancers. But molecular 
and genetic markers increase the accuracy of diagnosis, assist in subtyping bone 
tumors, and also provide an overview of target molecules for designing therapeutic 
approaches. The biomarkers can be specific or non-specific; diagnostic, prognostic, 
or therapeutic; and serological, genetic, or histological. The clinical presentation 
of bone tumors is non-specific, and the most common symptoms include pain 
and swelling. The clinical features involve limited movement, skin hyperthermia, 
weight loss, and the presence of a visible mass in the anatomical profile [11].
The serological markers are generally a reflection of osteoblastic and osteoclas-
tic activities in the bone [11]. As mentioned in the earlier sections, breast cancer 
metastases are mostly osteolytic, whereas metastases of prostate cancer are gener-
ally osteoblastic. Therefore, elevated levels of urinary N-terminal cross-linked 
telopeptide (NTx of type I collagen) and serum carboxyterminal cross-linked telo-
peptide (ICTP of type I collagen) in solid tumor patients and serum tartrate-resis-
tant acid phosphatase type 5b (TRAcP-5b) in patients with breast tumor metastasis 
can be used for diagnosis. On the other hand, serum levels of bone-specific alkaline 
phosphatase (BSAP), procollagen type I N-terminal propeptide (PINP), and OPG 
serve as the biomarkers for prostate cancer metastasis [11, 28].
With reference to the genetic changes, sarcomas can be divided into three cat-
egories: sarcomas with specific translocations (e.g., Ewing’s sarcoma, aneurysmal 
bone cyst), tumors with gene mutations or amplifications (e.g., chondrosarcomas, 
fibrous dysplasia), and sarcomas with genetic instability. These cytogenetic changes 
can be detected using banding and multicolor fluorescence in situ hybridization 
(FISH), array comparative genomic hybridization (array CGH), targeted detection 
techniques such as qPCR, and techniques to detect mutation [11].
There are several markers that are used for prognosis or diagnosis of different 
types of tumors that are discussed below:
4.1 Osteosarcoma
4.1.1 Serum markers
1. Degradation of collagen and the ground substance in the bone (due to pro-
longed exposure to fluoride) results in increased concentration of serum sialic 
acid that can be used as a serum biomarker for osteosarcoma [11].
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2. Expression of heat shock protein (HSP gp96), in the cytoplasm of osteo-
blastic sarcoma, has been found to be associated with pathogenesis of bone 
tumors. But it does not provide any idea regarding the degree of malig-
nancy [11].
3. The osteosarcoma patients displayed increased levels of endostatin, placental 
growth factor (PlGF), and FGF-1 and FGF-2 in serum [11].
4. Gas chromatography–mass spectrometry profiles of small-molecule 
metabolites in urine and serum samples of osteosarcoma patients displayed 
a disrupted energy metabolism, downregulated amino acid metabolism, and 
increase in glutathione metabolism and polyamine metabolism [11].
5. qPCR and western blot analysis for detection of IGF-1 receptor showed its 
increased expression in osteosarcoma tissues, suggesting it as a prognostic marker. 
Western blotting and enzyme-linked immunosorbent assay (ELISA) confirmed a 
decrease in serum levels of gelsolin in the osteosarcoma samples [11].
6. The presence of FGF-2 or leukemia inhibitory factor (Lif) serves as a bio-
marker, suggesting reduction of osteogenesis on osteosarcoma cells. Elevated 
serum levels of CXCL4 and CXCL in osteosarcoma patients affirmed the role 
of these markers in clinical manifestation. In addition to this, biomarker Snail2 
is also useful in prognosis of bone tumors [11].
7. Metastatic prostate cancers have been found to express the well-known mark-
ers of aggressiveness, namely, prostatic-specific antigen (PSA) [28].
8. Increase in erythrocyte sedimentation rate (ESR), alkaline phosphatase (ALP), 
and lactate dehydrogenase (LDH) are indicators of osteosarcoma [1, 8].
9. Immunohistochemistry of primary osteosarcomas showed expression of 
mitotic arrest defective protein 2 (MAD2). Immunohistochemical analysis of 
osteosarcoma biopsies indicated reduced expression of cysteine-rich protein 
with Kazal motifs (RECK). Immunohistochemistry analysis also showed 
expression of WNT-5a and ROR2 in patients with advanced stages of osteo-
sarcoma [11].
4.1.2 Genetic markers
Assessment of CCN3 expression levels at diagnosis may represent a useful 
molecular tool for early identification of patients with osteosarcoma. Gene altera-
tion of c-kit protein also serves as a prognostic marker for osteosarcoma. The 
transcriptional regulator, Oct-4, has been found to play a marked role in prolifera-
tion and spread of cancer. A reduced expression and inactivation of miR-34 gene 
have been reported to be associated with osteosarcomas. The action of miR-34 is 
p53 dependent. A dominant polymorphic variant of TGFβ receptor 1 (TGFBR1), 
TGFBR1*6A, is found to be associated with increased susceptibility of osteosar-
coma for metastasis. Bcl-xL, a member of Bcl-2 (B-cell lymphoma (BCL)) protein 
family, has been investigated to function as a dominant regulator of apoptotic 
cell death and plays an important role in malignant transformation. Cytotoxic 
T-lymphocyte antigen-4 (CTLA-4), a molecule that decreases immune response 
mediated by T cells, promotes development of osteosarcoma. Overexpressions of 
Cortactin (CTTN) gene, present in 11q13 amplicon, serve as a valid biomarker for 
osteosarcoma [11].
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4.2 Ewing’s sarcoma
Ewing’s sarcomas are associated with rearrangement of the EWS gene on 
chromosome 22q12 with an erythroblast transformation-specific (ETS) gene family 
member, resulting in formation of EWS-ETS fusion protein (EWS-FLI). FLI1 has 
been suggested as a useful marker particularly when hematolymphoid markers are 
negative. This translocation defines Ewing’s sarcoma family of tumors (ESFT) and 
provides a major tool for their accurate diagnosis. The translocation results in dif-
ferent types of genetic abnormalities, e.g., five forms of EWSR1-FLI1, three forms 
of EWSR1-ERG, and one form of EWSR1-FEV. A high expression of BMI-1 in ESFT 
cells was found to significantly affect survival and proliferation. Expression of 
CXCR4 has been reported to increase the risk of tumor metastases, whereas CXCR7 
expression is associated with shorter survival [11].
Ewing’s sarcoma has been reported to be associated with modulation of 
RANKL by VEGF-165, thus resulting in activation of osteoclast-mediated bone 
destruction [11].
4.3 Chondrosarcoma
On the basis of histological observations, chondrosarcomas are classified into 
three categories:
Grade I (low grade)—cytology similar to enchondroma and hyperchromatic 
plump nuclei of uniform size [11].
Grade II (intermediate grade)—increased cellularity, hyperchromasia, distinct 
nucleoli, and foci of myxoid alteration [11].
Grade III (high grade)—increased cellularity and nuclear atypia, occasional 
giant cells, abundant necrosis, and presence of mitosis [11].
4.3.1 Genetic markers
Deletions in the loci of CDKN2A, EXT1, and EXT2 genes, p53 mutation as late 
event in tumor progression, and amplification of 12q13 and loss of 9p21 are genetic 
aberrations found in conventional chondrosarcomas [11].
Higher expression of PTHR1 and Bcl-2 was found to be associated with increas-
ing histological grade in chondrosarcoma, suggesting its involvement in tumor 
progression. A higher expression of Aurora kinases A and B was relevant as prog-
nosis marker for chondrosarcoma. Somatic heterozygous isocitrate dehydrogenase 
1 (IDH1) hot spots (R132C and R132H) or IDH2 (R172S) mutations are specifically 
found in cartilaginous tumors [11].
4.3.2 Biological and molecular markers
qPCR analysis showed a high expression of COX-2 protein in solitary 
peripheral chondrosarcoma. Some of the studies reported a significant role of 
nitrotyrosine, COX-2, CD34, and lymphatic marker podoplanin with histologi-
cal grades of chondrosarcoma. Molecules such as integrin-linked kinase α and 
β-parvin and Mig-2 allow attachment of cells to matrix and govern cell motility 
and growth, thus playing an important role in progression and prognosis of 
chondrosarcomas [11].
Significantly high serum levels of receptor activator of nuclear factor-κB 
(RANK), OPG, IL-8, IL-6, and OPG/soluble RANKL ratio have been used to detect 
bone tumors. Osteosarcoma patients display a higher serum concentration of IL-16 
as compared to chondrosarcoma patients [33].
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5. Diagnosis
1. Radiographic diagnosis: Plain radiographs, computed tomography (CT) 
scans, and magnetic resonance imaging (MRI) are used to investigate the 
extent of tumors and to study the surrounding structure such as blood vessels, 
nerves, and soft tissues [1, 8].
2. Positron emission tomography (PET)-CT: [F-18]-Fluorodeoxy-D-glucose 
(FDG)-PET is a noninvasive imaging tool used for accurate discrimination 
between responding and nonresponding osseous tumors [1, 8].
3. Bone scintigraphy: This method involves total body scan and identifies axial 
and appendicular skeletal metastasis. It helps in determining intraosseous 
extension of tumors and sites of metastasis [1, 8].
4. Thallium scintigraphy: This method is used for determining tumor response 
to neoadjuvant (preoperative) chemotherapy when MRI is not helpful and also 
for detection of local recurrence [1].
5. Incisional or core needle biopsy is the final step in the diagnostic process. The 
tumor is staged using the Musculoskeletal Tumor Society staging scheme or 
the American Joint Commission on Cancer (AJCC) system [8].
6. Increased uptake of technetium diphosphonate in the clinical bone scans of 
osteolytic lesions in cancer patients also provides a diagnostic tool to identify 
increased cellular activity and metastasis [34].
Bone scans, X-rays, and histologic evaluation of autopsy specimens are com-
monly used for radiologic and histologic assessment of tumor sites [5].
6. Therapy
Osteosarcoma is typically treated with surgery and adjuvant chemotherapy that 
usually includes a combination of methotrexate, doxorubicin, and cisplatin [35]. 
Once the cancer has spread to the bones, it can rarely be cured, but often it can be 
treated to slow down its growth [36]. The therapeutic strategies for bone tumors 
should involve the following:
1. Treatment of cancer cells: This involves inhibition of tumor cell proliferation 
or killing of cancer cells to extend the patient’s survival time. This could be 
achieved by usage of cytotoxic drugs, hormonal deprivation, or inhibition of 
specific signaling pathways by targeted agents [4].
2. Disruption of the vicious cycle created due to complex biological signaling 
between cancer cells and bone resident cells [4].
3. Palliative therapies to reduce the extremely debilitating and painful symptom 
of bone metastasis and improve the quality of life for cancer patients [4].
As discussed in the previous sections, various signaling pathway are involved in 
the proliferation and migration of tumor cells. Targeting these signaling pathways by 
use of different inhibitors could hamper the survival of tumor cells. However, it has 
Hormone Therapy and Replacement in Cancer and Aging-related Diseases
12
already been known that the sex hormones play a major role in tumor cell survival 
and metastases. Thus, hormone therapy for curing tumors would basically involve 
hormone deprivation approaches. These strategies might inhibit the action of hor-
mones responsible to bone metastases, resulting in osteolytic or osteoblastic tumors.
6.1 Androgen deprivation therapy (ADT)
Ubiquitous and extensive expression of androgen receptor in the bone marrow 
of both males and females of all ages provides a direct evidence of action of andro-
gen on the bone marrow and offers clues to clinicopathological correlates [37]. Most 
prostate cancers and their stages depend upon androgen and androgen receptor 
(AR) for their growth and survival. Androgen receptor is a transcription factor that 
regulates the expression of several genes in response to binding of androgen (such 
as testosterone and dihydrotestosterone) and thus regulates the process of pro-
liferation and survival. As mentioned earlier, bone metastasis of prostate cancers 
majorly results in osteoblastic bone tumors [38]. Therefore, systemic treatment 
for advanced prostate cancer involves androgen deprivation therapy (ADT) that 
includes the following approaches:
a. To reduce the levels of circulating androgen by surgical or chemical castration. 
Surgical castration results in reduction of circulating androgen levels by >90% 
within 24 hours, whereas chemical castration is achieved by application of 
analogs of luteinizing hormone-releasing hormone (LH-RH) and results in 
reduction of circulating levels of testosterone [38].
LH-RH is a neurohormone, secreted by the hypothalamus, and regulates the 
secretion of gonadotropin, luteinizing hormone (LH), and follicle-stimulating 
hormone (FSH) from the pituitary. LH-RH acts via binding to its receptor, 
LH-RHR. These receptors have also been found in the cytoplasm of many tumor 
cells that involve both reproductive and nonreproductive tissues. LH-RH ago-
nists and antagonists have been found to downregulate these receptors and thus 
inhibit tumor growth [39]. Leuprolide acetate (Lupron, Eligard), goserelin acetate 
(Zoladex), triptorelin (Trelstar), and histrelin (Vantas) are some of the LH-RH 
agonists, whereas degarelix is an antagonist [4, 38]. LH-RHR can also be targeted 
specifically by peptides conjugated to anticancer drugs, thus developing cytotoxic 
analogs [39]. AN-152, commercially designated as AEZS-108, has been developed 
by conjugating 14-OH group of doxorubicin (DOX) to epsilon-amino group of 
D-Lys side chain of carrier peptide, through a glutaric acid spacer. The drug is 
endocytosed by cells through receptor-mediated endocytosis and thus selectively 
acts on cells that express its receptor. After internalization the drug is cleaved from 
the LH-RH moiety and accumulates in the nucleus. Because of receptor-mediated 
entry, the drug shows lesser side effects and also overcomes the resistance [39].
Administration of LH-RH agonist or antagonist for ADT not only results in 
suppression of testosterone to castration levels but also depletes estradiol, because 
it is derived by aromatization of testosterone [40]. Estradiol deficiency negatively 
impacts the bone health resulting in decline of bone mineral density (BMD) and 
increased risk of fractures [40]. This decrease in bone density also results in devel-
opment of renal stones leading to risk of urinary calculi [41]. Recently parenteral 
(e.g., intravenous, intramuscular, or transdermal) administration of estradiol has 
been investigated to suppress androgen production through negative feedback loop 
involving hypothalamic–pituitary axis and avoids fall in endogenous estradiol lev-
els. This also eliminates the risk of embolic cardiovascular toxicity that was caused 
due to oral administration of estradiol [40].
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b. To prevent binding of androgen to AR, by competitive inhibition using 
antiandrogens. These molecules compete with androgen for the ligand-binding 
domain of AR [38]. The antiandrogens can be of two categories, steroidal and 
nonsteroidal. Cyproterone acetate, a derivative of hydroxyprogesterone, is a 
steroidal antiandrogen and an antigonadotropin, which has a binding affinity 
for AR. But it has been found that it is not a pure antagonist but rather a partial 
agonist that adversely affects the survival of prostate cancer patients when 
combined with castration [38]. Among the nonsteroidal antiandrogens are the 
first-generation flutamide, nilutamide, and bicalutamide and second-genera-
tion enzalutamide and the cytochrome P450 c17 (CYP17, a critical enzyme in 
testosterone synthesis) inhibitor, abiraterone acetate, which prevents synthesis 
of androgens. Abiraterone inhibits 17-α-hydroxylase/17,20 lyase, a testosterone 
synthesis enzyme found in the adrenals, testis, and tumor [38, 42]. All these 
nonsteroidal antiandrogens are similar in terms of the chemical structure of 
their moiety that binds to the ligand-binding pocket [38]. It has been found that 
treatment with abiraterone acetate plus prednisone prolongs survival among 
patients with metastatic castration-resistant prostate cancer [42], though back 
pain, nausea, constipation, bone pain, arthralgia, urinary tract infection, 
edema, cardiac events, and elevation in levels of aminotransferase are some of 
the side effects associated with administration of abiraterone [42, 43].
Flutamide was the first nonsteroidal antiandrogen drug approved by the US 
Food and Drug Administration (FDA) for prostate cancer and forms the basis for all 
other nonsteroidal antiandrogens. The recommended dose of flutamide is 250 mg 
three times per day, so as to achieve a Cmax and Cmin of approximately 1.7 and 
0.8 μg/ml, respectively. It acts via blocking the binding of androgen to the ligand-
binding pocket of AR, resulting in inhibition of nuclear translocation of androgen-
bound AR. But improvement in disease upon cessation of flutamide treatment has 
been observed in patients, due to gain-of-function mutation in the ligand-binding 
domain of AR, T877A. Flutamide gets eliminated through the kidney, and liver 
toxicity is one of the common adverse effects [38].
Enzalutamide (previously called MDV3100) also acts via inhibiting the binding of 
androgen to AR, thus blocking its nuclear translocation and interaction with co-acti-
vators [4, 27, 38, 44]. Its recommended dose is 160 mg/day [38, 45]. However, clinical 
resistance due to gain-of-function mutation in AR ligand-binding domain (F876 L) and 
constitutive expression of active spice variants of AR that lack ligand-binding domain 
results in poor survival rates. Apalutamide and darolutamide also belong to the second 
generation of nonsteroidal antiandrogen that blocks the androgen binding to AR [38].
A novel first class of drug, ralaniten, is currently under clinical trials for patients 
who have previously received abiraterone, enzalutamide, or both. This class of 
drug binds to the unique region in the N-terminal domain of both full-length and 
truncated constitutively active splice variant of AR [38].
c. ADT that effectively reduces the serum testosterone levels has been a core tool 
for treating metastatic and advanced prostate cancer [46]. However, neoad-
juvant ADT has been suggested to have several advantages in prostate cancer 
patients undergoing transperineal prostate brachytherapy. The agents that are 
mainly used as adjuvant ADT include estrogens, antiandrogen monotherapy, 
and combined androgen blockade (CAB) using antiandrogen plus a gonadotro-
pin-releasing hormone receptor (GnRH) agonist. It has been reported that in 
comparison to GnRH agonist, degarelix, a GnRH receptor antagonist, is more 
efficient in achieving castration levels of testosterone and PSA, without risk of 
testosterone flare [46, 47].
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ADT is the mainstay of treatment for advanced prostate cancer, but eventual 
development of castration-resistant prostate cancer (CRPC) reduces the survival 
rates. One of the main reasons for development of CRPC is the sustained levels of 
androgen within the tumor due to suboptimal androgen suppression by primary 
ADT. Moreover, apart from the hormone-independent subsets, the other subsets 
of CRPC cells adapt themselves to the low testosterone environment induced by 
ADT and become hypersensitive to even lower concentrations of testosterone and 
other androgen precursors. Therefore, secondary hormone therapies are proving 
to be more efficient to achieve maximum suppression of testosterone. GTx-758 
(3-fluoro-N-(4-fluorophenyl)-4-hydroxy-N-(4-hydroxyphenyl) benzamide) is 
an oral nonsteroidal selective estrogen receptor (ERα) agonist that lowers the free 
testosterone and PSA levels by increasing sex hormone-binding globulin (SHBG). 
This also helps to avoid side effects related to estrogen deficiency [48].
Finasteride and dutasteride (5α-reductase enzyme inhibitors) are found to 
inhibit 5α-reductase-mediated conversion of testosterone to the high affinity 
androgen receptor ligand, 5α-dihydrotestosterone [49].
6.2 Selective estrogen receptor modulators (SERMs)
Estrogen is chemically related compounds derived from androgen precursors 
but contain a defining aromatic and hydroxyl group at the 17th position. Estrogens 
comprise the natural ligands for estrogen receptors (ERs), with 17β-estradiol being 
a potent agonist. 17β-estradiol has been reported to inhibit metastasis-associated 
lung adenocarcinoma transcript 1 (MALAT-1)-mediated osteosarcoma migration, 
invasion, metastasis, and induction of cell apoptosis, in an estrogen receptor α 
(ERα)-independent manner [15]. Earlier it was thought that binding of ER agonists 
induces a conformational change in the receptors, conferring the ability for co-
activators to bind, whereas ER antagonists were thought to compete for binding 
[50]. But later studies with tamoxifen revealed that the same molecule can behave as 
an agonist (tamoxifen acts as an estrogen agonist in the uterus, promoting hypertro-
phy) as well as an antagonist (tamoxifen exhibited estrogenic activity in the bone, 
thus protecting against bone loss), depending on the tissue context. Recently it has 
been found that oxysterols such as 27-hydroxycholesterol (27 HC) also modulate 
the activity of estrogen receptors (ERs) and are therefore classified as endogenous 
SERMs. 27 HC is derived from cholesterol in the presence of enzyme CYP27A1 
(cytochrome P450 enzyme). Breast cancer is the most common cancer in women, 
and its metastasis is majorly hormone (estrogen receptor) dependent. Some of the 
reports emphasize on the role of 27 HC in cancer progression and drug resistance, 
but several other reports also highlight its beneficial role in inhibiting proliferation 
and invasion of prostate cancer cells by blocking sterol-regulatory element-binding 
protein 2 (SREBP2). However, their different affinities for the different subtypes 
of ERs (α and β) and different relative expressions of these subtypes in tissues may 
explain some the of SERMs’ pharmacology. Recent evidence also suggests that bind-
ing of the receptor even by structurally related compounds could result in unique 
conformational changes, thus allowing recruitment of distinct sets of co-activators 
and/or corepressors to the receptor [50].
SERMs such as genistein, daidzein, and 4-hydroxytamoxifen have been reported 
to downregulate the expression of epidermal growth factor (EGFR) in vitro in 
osteosarcoma cells in an ER-dependent manner. The reduction in EGFR expression 
resulted in upregulation of markers for osteoblast differentiation, thus resulting in 
suppression of tumor cell proliferation [51].
Isoflavones such as genistein and daidzein are abundantly found in soybeans 
and soy-based food products. Isoflavones, coumestans, and lignans belong to a 
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class of phytoestrogens. Phytoestrogens are plant-derived substances that resemble 
17β-estradiol and can bind to activate intracellular estrogen receptors. These dietary 
phytoestrogens have been reported to exhibit bone-protecting effect without the 
risk of breast cancer [52].
Genistein has also been demonstrated to elicit different cell responses through 
different signaling mechanisms. A combination of genistein and 17β-estradiol has 
been shown to significantly increase apoptosis of breast cancer cells by increasing 
the BAX/BCL-2 (BCL-2-associated X protein (BAX)) ratio and reducing phos-
phorylation of extracellular signal-regulated kinase (ERK) ½ and AKT [53].
6.3 Activation of ERα
Osteosarcoma is a malignant tumor in the bone that originates from osteoblasts 
or osteoblast precursors. The reports clarify that normal osteoblasts express ERα, 
whereas osteosarcomas do not (due to promoter DNA methylation). Thus a treat-
ment strategy that involves induction of ERα expression in osteosarcoma cells in 
combination with estrogen administration would reduce proliferation of osteosar-
coma and increase cell differentiation. In vitro treatment of osteosarcoma cells with 
decitabine (DAC, 5-Aza-2′-deoxycytidine) has been found to induce the expression 
of ERα but reduce the expression of metastasis-associated markers such as vimen-
tin, slug, zeb1, and MMP9, with simultaneous decrease in stem cell markers such 
as SOX2, OCT4, and NANOG. Subsequent treatment with 17β-estradiol synergized 
with DAC in reducing cell proliferation and inducing differentiation markers such 
as alkaline phosphatase, osterix, and bone sialoproteins [21].
6.4 Estrogen inhibitors
The bone is the frequent site for metastasis of breast cancer. Estrogen plays a 
critical role in development and progression of breast cancer by interacting with 
ERα and ERβ. In postmenopausal women, estrogens (estrone and estradiol) are 
synthesized from androgens (androstenedione and testosterone) at extragonadal 
sites, including the breast. Thus the third generation of therapy involves inhibition 
of these aromatase enzymes, catalyzing the conversion of androgens to estrogens 
[54]. The aromatase inhibitors fall into two categories: steroidal and nonsteroidal. 
Letrozole and anastrozole are the third-generation nonsteroidal aromatase inhibi-
tors that block the extragonadal conversion of androgens to estrogens and give rise 
to an estrogen-depleted environment [49, 54, 55]. This lowers the estrogen in breast 
tissues and reduces their metastasis to the bone [54]. But in patients with hormone 
receptor-positive breast cancer, both the disease and its therapeutic treatment with 
antiestrogenic agents negatively impact the bone and result in decrease in bone 
mineral density. Therefore anti-hormonal therapy is considered only in cases where 
cancer cells express the ERα [56]. However, unlike nonsteroidal aromatase inhibi-
tors, a steroidal aromatase inhibitor, e.g., exemestane (probably due to its steroid 
structure), has been reported to exert beneficial effects on the bone through its 
primary metabolite 17-hydroexemestane [49, 55].
Fulvestrant, an alkylosulfonian derivative of estradiol, is another category of 
estrogen inhibitors (estrogen receptor antagonist), which competitively binds to 
ER with high affinity and downregulates expression of ERβ by functional blockade 
[57, 58]. Fulvestrant has been reported to induce mitochondrial depolarization at 
high concentrations that results in release of apoptogenic factors, loss of oxidative 
phosphorylation, and eventually cell death due to apoptosis [58].
2-Methoxyestradiol (2-ME) belongs to another class of anticancer drugs, which 
act via induction of neuronal nitric oxide synthase and generation of nitric oxide 
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in the nuclei of cancer cells. However, recently 2-ME has been found to activate 
epigenetically silenced ERβ, resulting in apoptosis of malignant cancer cells [58].
Furthermore, some of the recent reports emphasize the role of mutant ERα 
gene (ESR1) in cancer progression and drug resistance. These mutations have been 
observed to get accumulated in circulating DNA of bone metastasis patients [30].
6.5 Estrogen replacement
Zoledronic acid is a known anti-resorptive agent and exhibits antitumor effects 
in ER-ve breast cancers. Some of the recent studies emphasize that it’s the meno-
pausal status (and not the hormone receptor status) that determines its anticancer 
efficiency [59]. This differential effect of zoledronic acid in pre- and postmeno-
pausal bone metastasis patients has been suggested to be regulated by bone turnover 
effect of estrogen. Estrogen inhibits osteoclastogenesis via its direct effect on osteo-
clast and their precursors. Similarly, zoledronic acid also exhibits pro-apoptotic 
effects on osteoclasts by inhibiting mevalonate pathway and thus prevents release of 
growth factors that stimulate tumor growth. But in contrast to estrogen, zoledronic 
acid also reduces the number and activity of osteoblasts. Therefore, replacement 
of estrogen with zoledronic acid could be a more effective antitumor therapy in a 
low-estrogen bone microenvironment. Though administration of zoledronic acid 
does not alter growth of ER + ve cells at the primary site of tumor, it hampers their 
dissemination in the bone. As the cells evade the bone microenvironment, zole-
dronic acid-mediated bone turnover inhibits their proliferation and prevents overt 
metastases. Thus zoledronic acid could inhibit bone metastases of both ER-ve and 
ER + ve breast cancer cells [59].
One of the study reports dealing with in vitro microarray data analysis revealed 
that glucocorticoid was more efficient in controlling osteosarcoma cell growth than 
17β estradiol. Glucocorticoid upregulated the expression of tumor suppressor genes 
resulting in apoptosis and downregulated the oncogenes associated with cell cycle 
and mitosis, whereas estradiol had an opposite action [60].
7. Conclusion
Primary bone tumors are a rare occurrence, and most of the bone tumors arise 
due to metastases of breast, prostate, or lung cancers. The bone is the preferred 
site for metastases because of its highly vascular nature and extensive molecular 
signaling. A large number of bone tumor cases have been observed in an adolescent 
population experiencing a growth spurt and hormonal changes. Therefore, the 
treatment methodologies for bone tumors rarely involve the use of hormones as 
drugs but rather deal with hormone deprivation or inhibition. Though therapeutic 
approaches involving deprivation or replacement of hormones negatively affect 
bone health, the hormonal therapy alone or in combination with chemotherapeutic 
drugs offers a promising strategy for inhibition of bone tumors and improving the 
survival rates.
Acknowledgements
This article reflects collective intellectual wisdom of the authors. We thank 
Savitribai Phule Pune University, Pune, India, for providing the necessary infra-
structure during the compilation of this chapter. We also thank our colleagues, 
whose work has been cited in this article, for their inspiration.
17
Bone Tumors: Types and Treatments
DOI: http://dx.doi.org/10.5772/intechopen.86550
Author details
Geetanjali B. Tomar*, Jay R. Dave, Sayali S. Chandekar and Suhas T. Mhaske
Institute of Bioinformatics and Biotechnology, Savitribai Phule Pune University, 
Pune, India
*Address all correspondence to: geetanjalitomar13@gmail.com; joshigeet@gmail.com
Conflict of interest
The authors declare no conflict of interest with relation to this study.
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
18
Hormone Therapy and Replacement in Cancer and Aging-related Diseases
References
[1] Dai X, Ma W, He X, Jha RK. Review 
of therapeutic strategies for 
osteosarcoma, chondrosarcoma, and 
Ewing’s sarcoma. Medical Science 
Monitor. 2013;17:RA177-RA190. DOI: 
10.12659/msm.881893
[2] Ibrahim T, Mercatali L, Amadori 
D. Bone and cancer: The osteoncology. 
Clinical Cases in Mineral and Bone 
Metabolism. 2013;10:121-123. DOI: 
10.11138/ccmbm/2013.10.2.121
[3] Simmons JK, Hildreth BE, 
Supsavhad W, Elshafae SM, Hassan 
BB, Dirksen WP, et al. Animal models 
of bone metastasis. Veterinary 
Pathology. 2015;52:827-841. DOI: 
10.1177/0300985815586223
[4] Gdowski AS, Ranjan A, Vishwanatha 
JK. Current concepts in bone metastasis, 
contemporary therapeutic strategies 
and ongoing clinical trials. Journal 
of Experimental & Clinical Cancer 
Research; 2017;36:1-13. DOI: 10.1186/
s13046-017-0578-1
[5] Kakonen S-M, Mundy GR. 
Mechanisms of osteolytic bone 
metastases in breast carcinoma. 
Cancer. 2003;97:834-839. DOI: 10.1002/
cncr.11132
[6] Nakai Y, Okamoto K, Terashima A, 
Ehata S, Nishida J, Imamura T, et al. 
Efficacy of an orally active small-
molecule inhibitor of RANKL in bone 
metastasis. Bone Research. 2019;7:1-10. 
DOI: 10.1038/s41413-018-0036-5
[7] Schrage Y, Bovée J. Bone tumors: 
An overview. The Atlas of Genetics 
and Cytogenetics in Oncology and 
Haematology. 2011;9:166-170. DOI: 
10.4267/2042/38197
[8] Lindsey BA, Markel JE, Kleinerman 
ES. Osteosarcoma Overview. Rheuma-
tology and Therapy. 2016;4:25-43.  
DOI: 10.1007/s40744-016-0050-2
[9] Chakarun CJ, Forrester DM, 
Gottsegen CJ, Patel DB, White EA, 
Matcuk GR. Giant cell tumor of bone: 
Review, mimics, and new developments 
in treatment. Radiographics. 2013;33: 
197-211. DOI: 10.1148/rg.331125089
[10] Mak IWY, Turcotte RE, Ghert M. 
Parathyroid hormone-related protein 
(PTHrP) modulates adhesion, migration 
and invasion in bone tumor cells. 
Bone. 2013;55:198-207. DOI: 10.1016/j.
bone.2013.02.020
[11] Evola FR, Costarella L, Pavone 
V, Caff G, Cannavò L, Sessa A, 
et al. Biomarkers of osteosarcoma, 
chondrosarcoma, and ewing sarcoma. 
Frontiers in Pharmacology. 2017;8:1-14
[12] Schwab JH, Springfield DS, Raskin 
KA, Mankin HJ, Hornicek FJ. What’s 
new in primary bone tumors. Journal of 
Bone and Joint Surgery. 2012;94: 
1913-1919. DOI: 10.2106/JBJS.L.00955
[13] Li X, Yan ML, Yu Q. Identification 
of candidate drugs for the treatment 
of metastatic osteosarcoma through a 
subpathway analysis method. Oncology 
Letters. 2017;13:4378-4384. DOI: 
10.3892/ol.2017.5953
[14] El-Naggar AM, Clarkson PW, 
Negri GL, Turgu B, Zhang F, Anglesio 
MS, et al. HACE1 is a potential tumor 
suppressor in osteosarcoma. Cell Death 
& Disease. 2019;10. DOI: 10.1038/
s41419-018-1276-4
[15] Fang D, Yang H, Lin J, Teng Y, 
Jiang Y, Chen J, et al. 17β-Estradiol 
regulates cell proliferation, colony 
formation, migration, invasion and 
promotes apoptosis by upregulating 
miR-9 and thus degrades MALAT-1 in 
osteosarcoma cell MG-63 in an estrogen 
receptor-independent manner. 
Biochemical and Biophysical Research 
Communications. 2015;457:500-506. 
DOI: 10.1016/j.bbrc.2014.12.114
19
Bone Tumors: Types and Treatments
DOI: http://dx.doi.org/10.5772/intechopen.86550
[16] Yu PY, Gardner HL, Roberts R, Cam 
H, Hariharan S, Ren L, et al. Target 
specificity, in vivo pharmacokinetics, 
and efficacy of the putative STAT3 
inhibitor LY5 in osteosarcoma, Ewing’s 
sarcoma, and rhabdomyosarcoma. PLoS 
One. 2017;12:1-18. DOI: 10.1371/journal.
pone.0181885
[17] Wu VM, Mickens J, Uskoković 
V. Bisphosphonate-functionalized 
hydroxyapatite nanoparticles for the 
delivery of the bromodomain inhibitor 
JQ1 in the treatment of osteosarcoma. 
ACS Applied Materials & Interfaces. 
2017;9:25887-25904. DOI: 10.1021/
acsami.7b08108
[18] Onimoe GI, Liu A, Lin L, Wei CC, 
Schwartz EB, Bhasin D, et al. Small 
molecules, LLL12 and FLLL32, inhibit 
STAT3 and exhibit potent growth 
suppressive activity in osteosarcoma cells 
and tumor growth in mice. Investigational 
New Drugs. 2012;30:916-926.  
DOI: 10.1007/s10637-011-9645-1
[19] Zhang S, Wang X, Gu Z, Wang 
L. Small molecule survivin inhibitor 
YM155 displays potent activity against 
human osteosarcoma cells. Cancer 
Investigation. 2016;34:401-407. DOI: 
10.1080/07357907.2016.1212205
[20] Tovar C, Rosinski J, Filipovic Z, 
Higgins B, Kolinsky K, Hilton H, et al. 
Small-molecule MDM2 antagonists 
reveal aberrant p53 signaling in cancer: 
Implications for therapy. Proceedings 
of the National Academy of Sciences 
of the United States of America. 
2006;103:1888-1893. DOI: 10.1073/
pnas.0507493103
[21] Lillo Osuna MA, Garcia-Lopez 
J, El Ayachi I, Fatima I, Khalid 
AB, Kumpati J, et al. Activation of 
estrogen receptor alpha by decitabine 
inhibits osteosarcoma growth and 
metastasis. Cancer Research. 2018. DOI: 
10.1158/0008-5472.can-18-1255
[22] Svoboda M, Hamilton G, 
Thalhammer T. Steroid hormone 
metabolizing enzymes in benign 
and malignant human bone tumors. 
Expert Opinion on Drug Metabolism 
& Toxicology. 2010;6:427-437. DOI: 
10.1517/17425251003592129
[23] Guise TA. Molecular mechanisms 
of osteolytic bone metastases. Cancer. 
1999;88:15-16. DOI: 10.1002/1097-
0142(20000615)88:12+<2892::AID- 
CNCR2>3.0.CO;2-Y
[24] Nikitovic D, Kavasi RM, Berdiaki 
A, Papachristou DJ, Tsiaoussis J, 
Spandidos DA, et al. Parathyroid 
hormone/parathyroid hormone-related 
peptide regulate osteosarcoma cell 
functions: Focus on the extracellular 
matrix (review). Oncology Reports. 
2016;36:1787-1792. DOI: 10.3892/
or.2016.4986
[25] Weekes D, Kashima TG, Zandueta 
C, Perurena N, Thomas DP, Sunters A, 
et al. Regulation of osteosarcoma cell 
lung metastasis by the c-Fos/AP-1 target 
FGFR1. Oncogene. 2016;35:2852-2861. 
DOI: 10.1038/onc.2015.344
[26] Jiang M, Yan Y, Yang K, Liu Z, Qi 
J, Zhou H, et al. Small molecule nAS-E 
targeting cAMP response element binding 
protein (CREB) and CREB-binding 
protein interaction inhibits breast cancer 
bone metastasis. Journal of Cellular and 
Molecular Medicine. 2019;23:1224-1234. 
DOI: 10.1111/jcmm.14024
[27] Efstathiou E, Titus M, Wen 
S, Hoang A, Karlou M, Ashe R, 
et al. Molecular characterization of 
enzalutamide-treated bone metastatic 
castration-resistant prostate cancer. 
European Urology. 2015;67:53-60. DOI: 
10.1016/j.eururo.2014.05.005
[28] D’Oronzo S, Brown J, Coleman 
R. The value of biomarkers in bone 
metastasis. European Journal of Cancer 
Care. 2017;26:1-10. DOI: 10.1111/
ecc.12725
[29] Chirgwin JM, Wong DH, Corey 
E, Higgins LS, Stebbins EG, Guise TA, 
Hormone Therapy and Replacement in Cancer and Aging-related Diseases
20
et al. Basic mechanisms responsible 
for osteolytic and osteoblastic 
bone metastases. Clinical Cancer 
Research. 2006;12:6213s-6216s. DOI: 
10.1158/1078-0432.ccr-06-1007
[30] Bado I, Gugala Z, Fuqua SAW, 
Zhang XH-F. Estrogen receptors 
in breast and bone: From virtue of 
remodeling to vileness of metastasis. 
Oncogene. 2017;36:4527-4537. DOI: 
10.1038/onc.2017.94
[31] Bone Cancer: Introduction 
[Internet]. 2018. Available from: 
https://www.cancer.net/cancer-types/
bone-cancer/introduction
[32] Logothetis CJ, Lin SH. Osteoblasts 
in prostate cancer metastasis to bone. 
Nature Reviews. Cancer. 2005;5:21-28. 
DOI: 10.1038/nrc1528
[33] Kushlinskii NE, Timofeev YS, 
Solov’ev YN, Gerstein ES, Lyubimova 
NV, Bulycheva IV. Components of the 
RANK/RANKL/OPG system, IL-6, IL-8, 
IL-16, MMP-2, and calcitonin in the sera 
of patients with bone tumors. Bulletin 
of Experimental Biology and Medicine. 
2014;157:520-523. DOI: 10.1007/
s10517-014-2605-y
[34] Suva LJ, Washam C, Nicholas RW, 
Griffin RJ. Bone metastasis: Mechanisms 
and therapeutic opportunities. Nature 
Reviews Endocrinology. 2011;7:208-218. 
DOI: 10.1038/nrendo.2010.227
[35] Duan Z, Zhang J, Ye S, Shen J, 
Choy E, Cote G, et al. A-770041 
reverses paclitaxel and doxorubicin 
resistance in osteosarcoma cells. 
BMC Cancer. 2014;14:1-11. DOI: 
10.1186/1471-2407-14-681
[36] Macedo F, Ladeira K, Pinho F, 
Saraiva N, Bonito N, Pinto L, et al. Bone 
metastases: An overview. Oncology 
Reviews. 2017;11:43-49. DOI: 10.4081/
oncol.2017.321
[37] Mantalaris A, Panoskaltsis N, Sakai 
Y, Bourne P, Chang C, Messing EM, 
et al. Localization of androgen receptor 
expression in human bone marrow. The 
Journal of Pathology. 2001;193:361-366. 
DOI: 10.1002/1096-9896(0000)9999: 
9999<::AID-PATH803>3.0.CO;2-W
[38] Ito Y, Sadar MD. Enzalutamide and 
blocking androgen receptor in advanced 
prostate cancer: Lessons learnt from 
the history of drug development of 
antiandrogens. Research and Reports in 
Urology. 2018;10:23-32. DOI: 10.2147/
RRU.S157116
[39] Deivaraju C, Temple HT, Block N, 
Robinson P, Schally AV. LHRH receptor 
expression in sarcomas of bone and soft 
tissue. Hormone Molecular Biology and 
Clinical Investigation. 2016;28:105-111. 
DOI: 10.1515/hmbci-2016-0001
[40] Langley RE, Kynaston HG, Alhasso 
AA, Duong T, Paez EM, Jovic G, et al. 
A randomised comparison evaluating 
changes in bone mineral density in 
advanced prostate cancer: Luteinising 
hormone-releasing hormone agonists 
versus transdermal oestradiol. European 
Urology: European Association of 
Urology. 2016;69:1016-1025. DOI: 
10.1016/j.eururo.2015.11.030
[41] Diaz-Convalia E, Arrabal-Polo MA. 
Cano-Garcia M del C, Dominguez-Amillo 
A, Canales-Casco N, Arrabal-Martin 
M. Risk of renal stone formation in 
patients treated with luteinising hormone-
releasing hormone analogues for prostate 
cancer: Importance of bone metabolism 
and urine calcium. International Urology 
and Nephrology. 2018;50:419-425. DOI: 
10.1007/s11255-018-1793-1
[42] de Bono JS, Logothetis CJ, Molina 
A, Fizazi K, North S, Chu L, et al. 
Abiraterone and increased survival 
in metastatic prostate cancer. The 
New England Journal of Medicine. 
2011;364:1995-2005. DOI: 10.1056/
NEJMoa1014618
[43] Gravanis I, Lopez AS, Hemmings RJ, 
Jimenez JC, Garcia-Carbonero R,  
Gallego IG, et al. The European medicines 
21
Bone Tumors: Types and Treatments
DOI: http://dx.doi.org/10.5772/intechopen.86550
agency review of abiraterone for the 
treatment of metastatic castration-
resistant prostate cancer in adult men 
after docetaxel chemotherapy and in 
chemotherapy-naive disease: Summary of 
the scientific assessment of the committee 
for medicinal products for human use. 
The Oncologist. 2013;18:1032-1042. DOI: 
10.1634/theoncologist.2013-0092
[44] Body J-J, Casimiro S, Costa L. 
Targeting bone metastases in prostate 
cancer: improving clinical outcome. 
Nature Reviews Urology. 2015;12: 
340-356. DOI: 10.1038/nrurol.2015.90
[45] El-Amm J, Patel N, Freeman A, 
Aragon-Ching JB. Metastatic castration-
resistant prostate cancer: Critical review 
of enzalutamide. Clinical Medicine 
Insights: Oncology. 2013;7:235-245. DOI: 
10.4137/CMO.S11670
[46] Miki K, Sasaki H, Kido M, 
Takahashi H, Aoki M, Egawa S. A 
comparative study on the efficacies 
of gonadotropin-releasing hormone 
(GnRH) agonist and GnRH antagonist 
in neoadjuvant androgen deprivation 
therapy combined with transperineal 
prostate brachytherapy for localized 
prostate cancer. BMC Cancer. 2016;16: 
1-7. DOI: 10.1186/s12885-016-2737-8
[47] Kashiwabara T, Suda S. Usefulness 
of combined androgen blockade therapy 
with gonadotropin-releasing hormone 
antagonist for bone metastatic prostate 
cancer with pretreatment prostate-
specific antigen level ≥ 50 ng/mL. BMC 
Cancer. 2018;18:1-11. DOI: 10.1186/
s12885-018-4541-0
[48] Yu EY, Getzenberg RH, Coss CC, 
Gittelman MM, Keane T, Tutrone R, 
et al. Selective estrogen receptor alpha 
agonist GTx-758 decreases testosterone 
with reduced side effects of androgen 
deprivation therapy in men with 
advanced prostate cancer. European 
Urology: European Association of 
Urology. 2015;67:334-341. DOI: 
10.1016/j.eururo.2014.06.011
[49] Hofbauer LC, Rachner TD, 
Coleman RE, Jakob F. Endocrine 
aspects of bone metastases. The 
Lancet Diabetes and Endocrinology. 
2014;2:500-512. DOI: 10.1016/
S2213-8587(13)70203-1
[50] He S, Nelson ER. 
27-Hydroxycholesterol, an endogenous 
selective estrogen receptor modulator. 
Maturitas. 2017;104:29-35. DOI: 
10.1016/j.maturitas.2017.07.014
[51] Salvatori L, Caporuscio F, Coroniti 
G, Starace G, Frati L, Russo MA, 
et al. Down-regulation of epidermal 
growth factor receptor induced by 
estrogens and phytoestrogens promotes 
the differentiation of U2OS human 
osteosarcoma cells. Journal of Cellular 
Physiology. 2009;220:35-44. DOI: 
10.1002/jcp.21724
[52] Chrzan BG, Bradford PG. 
Phytoestrogens activate estrogen 
receptor β1 and estrogenic responses in 
human breast and bone cancer cell lines. 
Molecular Nutrition & Food Research. 
2007;51:171-177. DOI: 10.1002/
mnfr.200600091
[53] Rajah TT, Peine KJ, Du N, 
Serret CA, Drews NR. Physiological 
concentrations of genistein and 
17β-estradiol inhibit MDA-MB-231 
breast cancer cell growth by increasing 
BAX/BCL-2 and reducing pERK1/2. 
Anticancer Research. 2012;32:1181-1191
[54] Wang W, Belosay A, Yang X, 
Hartman JA, Song H, Iwaniec UT, et al. 
Effects of letrozole on breast cancer 
micro-metastatic tumor growth in bone 
and lung in mice inoculated with murine 
4T1 cells. Clinical & Experimental 
Metastasis. 2016;33:475-485. DOI: 
10.1007/s10585-016-9792-z
[55] Ariazi EA, Leitao A, Oprea 
TI, Chen B, Louis T, Bertucci AM, 
et al. Exemestane’s 17-hydroxylated 
metabolite exerts biological effects 
as an androgen. Molecular Cancer 
Hormone Therapy and Replacement in Cancer and Aging-related Diseases
22
Therapeutics. 2007;6:2817-2827. DOI: 
10.1158/1535-7163.mct-07-0312
[56] Bartels S, Christgen M, Luft A, 
Persing S, Jödecke K, Lehmann U, et al. 
Estrogen receptor (ESR1) mutation in 
bone metastases from breast cancer. 
Modern Pathology. 2018;31:56-61. DOI: 
10.1038/modpathol.2017.95
[57] Kang E, Cho JH, Choi J-H, Yoo 
H-W. Etiology and therapeutic outcomes 
of children with gonadotropin-
independent precocious puberty. 
Annals of Pediatric Endocrinology & 
Metabolism. 2016;21:136. DOI: 10.6065/
apem.2016.21.3.136
[58] Gorska M, Wyszkowska RM, 
Kuban-Jankowska A, Wozniak M. 
Impact of apparent antagonism 
of estrogen receptor β by 
fulvestrant on anticancer activity 
of 2-methoxyestradiol. Anticancer 
Research [Internet]. 2016;36:2217-2226. 
Available from: http://www.ncbi.nlm.
nih.gov/pubmed/27127126
[59] Holen I, Walker M, Nutter F, 
Fowles A, Evans CA, Eaton CL, et al. 
Oestrogen receptor positive breast 
cancer metastasis to bone: inhibition by 
targeting the bone microenvironment 
in vivo. Clinical & Experimental 
Metastasis. 2016;33:211-224. DOI: 
10.1007/s10585-015-9770-x
[60] Zhou Q , Shen L, Liu C, Liu C, Chen 
H, Liu J. The effects of estradiol and 
glucocorticoid on human osteosarcoma 
cells: Similarities and differences. 
Anticancer Research. 2016;36:1683-1691
[61] Bone Cancer: Statistics [Internet]. 
Nov. 2018. Available from: https://www.
cancer.net/cancer-types/bone-cancer/
statistics
[62] Dorfman HD, Vanel D, 
Czerniak B, Park YK, Kotz R, Unni 
KK. WHO classification of tumours 
of bone: Introduction. World Health 
Organization. 2013:226-232
